Value
5.8/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 3.5 |
| Fwd P/E | 9.0 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 11.7x
- ▸PEG: 0.01
TVTX · Why this verdict
Why Travere Therapeutics (TVTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue has grown 56% year over year, among the highest growth rates in the batch, driven by the commercial launch of FILSPARI, with three of the last four quarters producing large positive earnings surprises including 794% and 187% beats. Growth breakdown | Revenue growth exceeds 30% year over year in the next reported annual period, confirming that FILSPARI adoption is accelerating. | →Stable |
| CounterFILSPARI is identified as a product concentration risk; if clinical evidence weakens, competition emerges, or label restrictions are imposed, the entire growth engine could stall rapidly. | ||
Both FILSPARI and Thiola depend on sole-source manufacturers, creating a supply chain vulnerability where any disruption at a single manufacturing facility could halt commercial supply and materially damage revenue. Bear case | Travere adds at least one additional qualified manufacturer for either FILSPARI or Thiola within the next 18 months, reducing single-point supply risk. | →Stable |
| CounterSole-source manufacturing relationships are common in specialty pharma and are typically structured with large safety stocks and redundant quality systems that reduce actual supply disruption risk. | ||
The company is burning cash at negative 10% of revenue, and despite the earnings beats, the free cash flow quality score reflects ongoing cash consumption, meaning continued operations depend on either accelerating FILSPARI cash collections or eventual financing. Quality breakdown | Free cash flow turns positive within the next 2 annual periods as FILSPARI revenue scales above the fixed cost base. | →Stable |
| CounterA 56% revenue growth rate at negative 10% FCF margin is a relatively controlled burn for a commercial-stage biotech; the trajectory toward cash flow breakeven appears achievable within 2 years at current growth. | ||
A 20% short interest and a stock price already 9.2% above analyst price targets create a combined risk where there is no near-term catalyst visible to make short sellers cover, while the negative asymmetry means the reward-to-risk ratio is already unfavorable. Key risks | Short interest falls below 12% and analyst price targets are revised upward to at least $60 within the next 6 months. | →Stable |
| CounterWith RSI at 70 and rising on-balance volume, the stock is being aggressively bought by growth investors despite high short interest, and a squeeze could drive prices materially above current analyst targets. | ||
Revenue has grown 56% year over year, among the highest growth rates in the batch, driven by the commercial launch of FILSPARI, with three of the last four quarters producing large positive earnings surprises including 794% and 187% beats.
→StableGrowth breakdown
- Expectation
- Revenue growth exceeds 30% year over year in the next reported annual period, confirming that FILSPARI adoption is accelerating.
CounterFILSPARI is identified as a product concentration risk; if clinical evidence weakens, competition emerges, or label restrictions are imposed, the entire growth engine could stall rapidly.
Both FILSPARI and Thiola depend on sole-source manufacturers, creating a supply chain vulnerability where any disruption at a single manufacturing facility could halt commercial supply and materially damage revenue.
→StableBear case
- Expectation
- Travere adds at least one additional qualified manufacturer for either FILSPARI or Thiola within the next 18 months, reducing single-point supply risk.
CounterSole-source manufacturing relationships are common in specialty pharma and are typically structured with large safety stocks and redundant quality systems that reduce actual supply disruption risk.
The company is burning cash at negative 10% of revenue, and despite the earnings beats, the free cash flow quality score reflects ongoing cash consumption, meaning continued operations depend on either accelerating FILSPARI cash collections or eventual financing.
→StableQuality breakdown
- Expectation
- Free cash flow turns positive within the next 2 annual periods as FILSPARI revenue scales above the fixed cost base.
CounterA 56% revenue growth rate at negative 10% FCF margin is a relatively controlled burn for a commercial-stage biotech; the trajectory toward cash flow breakeven appears achievable within 2 years at current growth.
A 20% short interest and a stock price already 9.2% above analyst price targets create a combined risk where there is no near-term catalyst visible to make short sellers cover, while the negative asymmetry means the reward-to-risk ratio is already unfavorable.
→StableKey risks
- Expectation
- Short interest falls below 12% and analyst price targets are revised upward to at least $60 within the next 6 months.
CounterWith RSI at 70 and rising on-balance volume, the stock is being aggressively bought by growth investors despite high short interest, and a squeeze could drive prices materially above current analyst targets.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Travere Therapeutics has delivered 56% revenue growth and three consecutive earnings beats with an average surprise above 300%, driven by its FILSPARI product, but the stock has exceeded analyst targets, carries 20% short interest, and is burning cash at negative 10% of revenue.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 7.2 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.9 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -10% of revenue
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 56% YoY
Momentum
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 2.8 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.3 |
- ▸Overbought (RSI 78)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 5.4 |
| erm sentiment | 5.0 |
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $14,325,811 (0.271% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.8 |
| growth rank | 7.0 |
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.0 |
| support resistance | 2.1 |
| 52w position | 8.9 |
Risk (lower is worse)
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 3.4 |
| volatility | 3.2 |
| put call | 0.5 |
| implied vol | 0.0 |
| beta | 6.6 |
| debt equity | 1.7 |
- ▸High short interest justified: 19%
- ▸Elevated put/call: 1.93
- ▸High IV: 93%
- ▸Concentration risks: 2 HIGH, 2 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (4)
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.6<4.5
- ASYMMETRY:-0.7=NEGATIVE
Warning (2)
- INSIDER:0.27%=MODERATE
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.72
Upside
-10.8%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.6<4.5.
The strongest dimensions are Growth at 10.0, Catalyst at 7.5, and Sentiment at 6.6; the weakest are Risk (lower is worse) at 2.4, Insider at 3.3, and Quality at 3.3. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of -0.72 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Filspari Revenue Growth
Trip ifRevenue growth falls below 20% year over year in any reported period over the next 12 months.
- P2Product Supplier Concentration
Trip ifA supply disruption reduces FILSPARI or Thiola availability for more than 30 days, causing quarterly revenue to fall below 80% of analyst expectations.
- P3Cash Burn Rate
Trip ifCash burn rate exceeds 20% of revenue for more than 2 consecutive quarters.
- P4High Short Interest Target Exceeded
Trip ifShort interest rises above 25% and stock price drops below $45, more than 16% below the current $53.80.